HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A L Harris Selected Research

5-(2-formyl-3-hydroxyphenoxy)pentanoic acid

6/2000Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


A L Harris Research Topics

Disease

87Neoplasms (Cancer)
01/2022 - 01/2000
74Hypoxia (Hypoxemia)
01/2017 - 01/2000
35Breast Neoplasms (Breast Cancer)
01/2022 - 02/2000
14Necrosis
08/2016 - 03/2000
13Carcinoma (Carcinomatosis)
09/2006 - 01/2000
12Neoplasm Metastasis (Metastasis)
01/2017 - 03/2001
10Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2015 - 01/2000
8Urinary Bladder Neoplasms (Bladder Cancer)
08/2016 - 01/2000
8Renal Cell Carcinoma (Grawitz Tumor)
08/2006 - 01/2000
6Colorectal Neoplasms (Colorectal Cancer)
01/2016 - 01/2000
6Adenocarcinoma
10/2010 - 10/2001
5Ductal Carcinoma
02/2014 - 10/2000
5Kidney Neoplasms (Kidney Cancer)
03/2013 - 07/2001
4Lung Neoplasms (Lung Cancer)
02/2015 - 01/2000
4Squamous Cell Carcinoma of Head and Neck
03/2011 - 07/2001
4Lymphatic Metastasis
11/2005 - 11/2000
4Head and Neck Neoplasms (Head and Neck Cancer)
11/2001 - 02/2000
4Melanoma (Melanoma, Malignant)
12/2000 - 01/2000
3Burns
08/2015 - 02/2008
3Pituitary Neoplasms (Pituitary Adenoma)
08/2000 - 03/2000
2Prostatic Neoplasms (Prostate Cancer)
01/2022 - 02/2000
2Glioblastoma (Glioblastoma Multiforme)
10/2015 - 05/2001
2Noninfiltrating Intraductal Carcinoma (DCIS)
07/2014 - 03/2001
2Adenoma (Adenomas)
05/2013 - 05/2000
2Carcinogenesis
07/2010 - 12/2001
2Pathologic Processes
09/2008 - 01/2002
2Endometrial Neoplasms (Endometrial Cancer)
02/2008 - 11/2001
2Lymphoma (Lymphomas)
02/2005 - 01/2000
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2004 - 01/2000
2Inflammatory Breast Neoplasms
05/2004 - 03/2003

Drug/Important Bio-Agent (IBA)

44Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2017 - 01/2000
32Proteins (Proteins, Gene)FDA Link
08/2016 - 01/2000
18Messenger RNA (mRNA)IBA
02/2014 - 01/2000
16Thymidine PhosphorylaseIBA
05/2005 - 01/2000
14Carbonic Anhydrase IXIBA
01/2017 - 07/2001
11Oxygen (Dioxygen)IBA
10/2015 - 06/2000
10Transcription Factors (Transcription Factor)IBA
08/2015 - 01/2000
9Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
07/2014 - 01/2000
9Monoclonal AntibodiesIBA
11/2007 - 01/2000
8Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
09/2006 - 01/2000
7EnzymesIBA
10/2015 - 02/2000
7Biological ProductsIBA
07/2014 - 04/2001
6MicroRNAs (MicroRNA)IBA
08/2016 - 10/2010
6Biomarkers (Surrogate Marker)IBA
08/2016 - 12/2000
6DNA (Deoxyribonucleic Acid)IBA
08/2015 - 01/2000
6Pharmaceutical PreparationsIBA
01/2015 - 01/2000
6Carbonic Anhydrases (Carbonic Anhydrase)IBA
01/2009 - 12/2000
6ParaffinIBA
09/2003 - 02/2000
5Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
09/2012 - 01/2000
5LigandsIBA
08/2012 - 11/2000
5Ribonucleases (Ribonuclease)IBA
08/2005 - 11/2000
4Estrogen ReceptorsIBA
08/2013 - 11/2000
4AntibodiesIBA
11/2009 - 05/2001
4Indicators and Reagents (Reagents)IBA
02/2008 - 02/2000
4CytokinesIBA
02/2008 - 01/2000
4Hypoxia-Inducible Factor 1IBA
01/2007 - 09/2001
4Complementary DNA (cDNA)IBA
08/2005 - 04/2000
3RNA (Ribonucleic Acid)IBA
01/2022 - 07/2008
3Small Interfering RNA (siRNA)IBA
01/2017 - 07/2010
3Protein Isoforms (Isoforms)IBA
02/2015 - 07/2000
3Hormones (Hormone)IBA
07/2014 - 02/2000
3MitogensIBA
08/2012 - 03/2000
3Phosphotransferases (Kinase)IBA
08/2012 - 07/2001
3Captopril (Capoten)FDA LinkGeneric
03/2005 - 01/2000
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2004 - 03/2000
3FibrinIBA
04/2004 - 03/2003
3Peptides (Polypeptides)IBA
03/2004 - 01/2000
3EpitopesIBA
11/2001 - 01/2000
3Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
04/2001 - 07/2000
3Vascular Endothelial Growth Factor CIBA
04/2001 - 07/2000
3TamoxifenFDA LinkGeneric
06/2000 - 01/2000
2Amino AcidsFDA Link
01/2022 - 01/2016
2Glucose (Dextrose)FDA LinkGeneric
01/2022 - 02/2015
2Glutamine (L-Glutamine)FDA Link
01/2016 - 07/2014
2Lipoproteins (Lipoprotein)IBA
10/2015 - 07/2014
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2015 - 06/2011
2Letrozole (Femara)FDA LinkGeneric
01/2015 - 04/2013
2Celecoxib (Celebrex)FDA Link
07/2014 - 06/2011
2Beclin-1IBA
05/2013 - 10/2010
2Insulin-Like PeptidesIBA
08/2012 - 01/2000
2Reactive Oxygen Species (Oxygen Radicals)IBA
08/2012 - 05/2005
2Activating Transcription Factor 4IBA
08/2010 - 07/2008
2Activating Transcription Factor 3IBA
02/2010 - 01/2007
2Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
11/2009 - 01/2009
2ZincIBA
07/2009 - 08/2000
2Cell-Free Nucleic AcidsIBA
09/2008 - 03/2004
2Lactic Acid (Lactate)FDA LinkGeneric
06/2008 - 09/2003
2Oxidoreductases (Dehydrogenase)IBA
06/2008 - 02/2000
2Thromboplastin (Tissue Factor)IBA
10/2005 - 03/2005
2Dalteparin (Dalteparin Sodium)FDA Link
03/2005 - 07/2004
2marimastatIBA
03/2005 - 07/2004
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2005 - 01/2000
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
02/2005 - 05/2000
2Cadherins (E-Cadherin)IBA
06/2003 - 03/2003

Therapy/Procedure

32Therapeutics
08/2015 - 01/2000
11Radiotherapy
08/2016 - 01/2000
11Drug Therapy (Chemotherapy)
08/2015 - 01/2000
4Neoadjuvant Therapy
10/2016 - 12/2006
4Chemoradiotherapy
11/2001 - 01/2000
2Synchrotrons
07/2009 - 06/2008